One senior toxicologist (at least 10 years of experience) with in-depth knowledge of dioxin-like toxicity and the TEF concept, i.e with particular emphasis on the use of REP data (including systemic plasma-based REPs) for dioxin-like compounds for the derivation of TEFs compared to 2,3,7,8-TCDD from in vivo and in vitro studies as shown by publications in these fields.Requirement 2: Ability to provide a team of experts compliant with these specific expertise requirements:.Requirement 1: The tenderer overall must have extensive and demonstrable experience in toxicology and risk assessment in the area of dioxins and dioxin-like compounds, including PCBs, and.Selection criteria - technical and professional capacity:.To prepare a working document for the upcoming WHO meeting in 2022 that evaluates the impact on dioxin TEF derivation of new REP data (including systemic plasma-based REPs) based on newly published in vitro and in vivo studies since the last WHO re-evaluation in 2005.To carry out a peer review of the contents of a database of relative effect potencies of PCDDs, PCDFs and PCBs according to the criteria and guidance defined by WHO’s expert group in charge of the re-evaluation of TEFs in 2022.This evaluation should also include a feasibility analysis of the use of in vitro and systemic REPs/TEFs for human risk assessment. in plasma) of dioxin-like compounds (systemic TEFs) for human risk assessment with the present state of art in toxicology for these compounds (Van Ede et al., 2016). In addition, it should contain a review of the use of TEFs based on systemic levels (e.g. This working document should critically review how the use of REP data derived from both in vivo and in vitro types of studies impact the derivation of TEFs for dioxin-like compounds. The second aim of this procurement procedure is to ensure the preparation of a working document to be used at the WHO expert meeting. Through this procurement procedure, EFSA aims to ensure and support the independent peer review of the before mentioned updated REP-database prior to the international re-evaluation of TEFs by the WHO in the spring of 2022. The WHO expert group that will conduct the re-evaluation of TEFs in 2022 considers it crucial that before the REP-database can be used, it is peer reviewed by an independent organisation to ensure that it contains REP data from studies selected on the basis of principles and criteria defined earlier by the WHO. WHO will take as starting point for their re-evaluation a database of Relative Effect Potencies (REP) updated using the same criteria for inclusion/exclusion of studies in the database as those applied in the 2005 evaluation by WHO (Fitch et al., 2019 Haws et al., 2006 Van den Berg et al., 2006). Background: WHO has planned to re-evaluate the Toxic Equivalency Factors (WHO-TEFs) that are worldwide used to estimate the total dioxin-like activity of mixtures of polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs) and polychlorinated biphenyls (PCBs) in an expert meeting in spring of 2022.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |